Fluorescein Angiographic Findings of Peripheral Retinal Vasculature after Intravitreal Conbercept versus Ranibizumab for Retinopathy of Prematurity

Table 3

Number of eyes (%) with peripheral retinal vasculature abnormalities for ROP infants receiving intravitreal conbercept or ranibizumab.

	Intravitreal conbercept	Intravitreal ranibizumab
Avascular zone, N (%)	28 (96.55%)	23 (92.00%)	0.591
Leakage, N (%)	7 (24.14%)	10 (40.00%)	0.689
Blunting, N (%)	28 (96.55%)	25 (100.00%)	1.0
Dilation, N (%)	21 (72.41%)	15 (60.00%)	0.335
Loops, N (%)	23 (79.31%)	16 (64.00%)	0.210
Arteriovenous shunt, N (%)	14 (48.28%)	9 (36.00%)	0.363
Capillary dropout, N (%)	19 (68.97%)	17 (68.00%)	0.847